small molecule glp-1 agonist Drug Hunter's 2023 Patent Review of GLP-1R Agonists | Drug Hunter posted on the topic Binding sites and design strategies

In support of this, ICV administration of GLP-1 in rats has been shown to attenuate the fasting-induced rise in NPY/AgRP expression and decreases fasting-induced inhibition of POMC/CART expression in the ARC (Seo et al., 2008)

Dual GLP-1/GIP receptor agonists (molecules engineered to simultaneously activate GLP-1R and GIPR) represent a pharmacological leap beyond classical incretin-based therapies

Following this, there have been two clinical phase 2 trials (SAR425899 and MEDI0382 also known as cotadutide) published evaluating GLP-1/glucagon receptor co-agonists

GLP-1 is both anxiogenic and antidepressant

Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk

A.ChanM.DesaiA